Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities
Boehringer Ingelheim has entered a partnership with the NCD Alliance, a network dedicated to shaping a world in which everyone...
Disability
Shearwater Health Partners with Laguna Health, Leveraging Cutting-Edge AI Solutions
The partnership enables Shearwater to integrate advanced conversational AI and real-time insights into its Clinical Process Outsourcing operations NASHVILLE, Tenn.,...
AudioEye Achieves HIPAA Compliance and SOC 2 Type II Certification, Strengthening Data Protection and Security Measures for Its Customers
New compliance and certification measures unlock opportunities in healthcare and enterprise TUCSON, Ariz., Sept. 26, 2024 /PRNewswire/ -- AudioEye, Inc. (Nasdaq:...
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
Nes-Ziona, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
-- Poster to be presented at ACR Convergence annual meeting -- TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pacira...
InBrain Pharma to Present Positive Results from Its DIVE-I Phase I/II Clinical Trial for Parkinson’s Disease at the Congress of Parkinson’s Disease and Movement Disorders from September 27 to October 1 in Philadelphia
Lille, September 25, 2024 - InBrain Pharma, a biopharmaceutical company specialized in neurodegenerative diseases, will present the positive results of its...
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
$185+ million in incremental orders for ACAM2000® and VIGIV to be delivered in 2024 and 2025GAITHERSBURG, Md., Sept. 25, 2024...
Ottobock Continues Providing Technical Service for Invictus Games Vancouver Whistler 2025
The medical technology company supports competitors in the first ever Winter hybrid Invictus GamesBURLINGTON, ON / ACCESSWIRE / September 24,...
Ottobock Continues Technical Service for Invictus Games Vancouver Whistler 2025
The medical technology company supports competitors in the first-ever Winter hybrid Invictus GamesAUSTIN, TX / ACCESSWIRE / September 24, 2024...
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
Nes-Ziona, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
Potential of George Medicines’ novel, low-dose, triple combination pill to transform management of hypertension highlighted at global congress
London, UK 24 September 2024 – George Medicines, a late-stage, biopharmaceutical company addressing significant unmet need in the treatment of...
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for...
Stryker completes acquisition of NICO Corporation, expanding minimally invasive solutions for brain tumor removal and stroke care
PORTAGE, Mich., USA, Sept. 20, 2024 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it...
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase...
Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines
New patent expected to expire in 2030 Tosymra® (sumatriptan nasal spray) 10mg is indicated and marketed for the acute treatment...
New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis
Infusion related reactions in patients receiving 30-minute BRIUMVI infusions were all mild (Grade 1) and resolved completely Data also demonstrate...
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50...
ReWalk Robotics Ltd. Finalizes Corporate Name Change to Lifeward Ltd.
Following approval by the shareholders and the Israel Companies Registrar, Lifeward has completed is rebranding initiative with a formal name...
South Korean Startup DoctorPresso Launches Groundbreaking App That Detects Depression Through Voice
A New Era of Mental Health: Meet REDI, the App That Listens for Depression SEOUL, South Korea, Sept. 12, 2024...
Veru to Present at the 2024 Cantor Global Healthcare Conference
MIAMI, FL, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...